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Schizophrenia and bipolar disease are 
complex diseases, with multiple genes 
and environmental factors thought to 
be responsible for their manifestation. 
Many reports have implicated changes in 
certain regions of the human genome in 
schizophrenia. An area on Chromosome 
1 has been associated with the disease 
in different studies and populations. 
Linda Brzustowicz and colleagues had 
previously described association of 
several single nucleotide polymorphisms 
(SNPs) within a gene called CAPON (for 
carboxyl-terminal PDZ ligand of neuronal 
nitric oxide synthase) with schizophrenia 
in a set of Canadian families. A separate 
study in a Chinese population found 
an association between schizophrenia 
and a separate group of SNPs within 
CAPON.CAPON is an attractive candidate 
for a “schizophrenia gene”: CAPON was 
ﬁ  rst identiﬁ  ed as a protein binding to 
neuronal nitric oxide synthase (nNOS), 
and indirect evidence suggests that it 
might be linked to the regulation of 
glutamate neurotransmission. However, 
so far, no coding sequence mutations in 
CAPON have been found in patients with 
schizophrenia. 
Brzustowicz and colleagues now 
report results from a study of CAPON 
expression in postmortem brain samples 
from patients with schizophrenia, from 
patients with bipolar disorder, and from 
control individuals without psychiatric 
illness. Initially screening a human 
fetal brain cDNA library for potential 
alternative splice forms of CAPON, they 
found, in addition to the predicted full-
length transcript, a shorter isoform that 
consists of the last two exons of the gene. 
They also conﬁ  rmed that both long and 
short versions of the protein are present 
in human brain. (The short isoform 
would still be able to bind nNOS and 
possibly disrupt its interaction with other 
proteins.)
The authors then examined CAPON
mRNA expression in postmortem 
brain samples from 35 patients with 
schizophrenia, from 35 patients with 
bipolar disorder, and from 35 controls. 
They looked for transcripts encoding the 
long and short forms and also compared 
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Tumor vaccination has perhaps been 
one of the most eagerly anticipated 
developments in cancer medicine. 
Research efforts in melanoma started 
with early unsuccessful attempts to 
induce a nonspeciﬁ  c immune response 
with Bacillé Calmette-Guerin (BCG). 
Subsequent vaccines combined BCG 
with autologous tumor cells or mixtures 
of allogeneic tumor cells, with varying 
responses. Most recently, however, 
work has focused on trying to produce 
a speciﬁ  c immune response using 
melanoma-derived peptide antigens. 
The antigens most commonly used 
are melanoma antigen recognized 
by T lymphocytes (MART-1)/Melan A, 
glycoprotein (gp) 100, and tyrosinase, 
all of which occur on both normal 
melanocyes and melanoma cells; 
randomized trials are currently under way 
on these vaccines. 
However, the response of patients 
to these vaccines has been extremely 
variable and hard to predict. Ideally, 
researchers want to track antigen-speciﬁ  c 
T cells and measure their activation, but 
current assays are cumbersome and 
require large volumes of blood. Now, 
Mark Davis and colleagues from Stanford 
University and the University of Southern 
California present a high-throughput 
method for analyzing the response of 
patients to these vaccines, by means of 
an array that captures speciﬁ  c T cells, 
activates them, and then measures their 
response to activation. 
The researchers demonstrated the 
usefulness of this approach by studying 
ten patients from a phase II trial of 60 
patients who had stage IIC/III and IV 
melanoma and who had been vaccinated 
with a combination of MART-1, gp100, 
and tyrosinase. They describe the use 
of peptide major histocompatibility 
complex arrays, which immobilizes CD8T 
cells, activates them, and then measures 
the degree of activation by the secretion 
of cytokines. The major new technical 
development is the method of measuring 
the amounts of cytokines released by 
means of labeled antibodies also present 
on the array.
What they found was a startling 
diversity of responses to vaccination. 
However, one predictor of good clinical 
response to vaccination was strong 
secretion of both interferon-γ and tumor 
necrosis factor-α; four of the four patients 
with this pattern of secretion remained 
free of melanoma recurrence, whereas 
only two of the six patients in whom 
there were marked differences in the 
secretion of these two cytokines were 
free of recurrence.
Where does this paper leave the 
ﬁ  eld of research on tumor vaccination? 
It provides a detailed snapshot of T 
cell responses in individual patients, 
and if these patterns of responses are 
substantiated in larger numbers of 
patients, it may well allow doctors to 
begin to understand who is likely to 
respond to one of these vaccines. What 
it does not do is explain why vaccine 
responses vary so much among patients; 
this is a far more complex question.
Chen DS, Soen Y, Stuge TB, Lee PP, Weber 
JS, et al. (2005) Marked differences in 
human melanoma antigen-speciﬁ  c T cell 
responsiveness after vaccination using 
a functional microarray. DOI: 10.1371/
journal.pmed.0020265
Measuring the Immune Response to Tumor Vaccination
DOI: 10.1371/journal.pmed.0020360
DOI: 10.1371/journal.pmed.0020360.g001
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expression levels (relative to beta-actin) 
across the diagnostic groups. In the 
dorsolateral prefrontal cortex (thought to 
be involved in schizophrenia and the only 
area for which samples were available), 
expression levels of the long isoform did 
not differ between patient and control 
samples. However, the short isoform was 
expressed at higher levels in the patients 
with mental illness than in the controls. 
They also analyzed DNA from these 
individuals at three SNPs associated with 
schizophrenia and found, for each SNP, 
that the group of individuals who carried 
one or two copies of the schizophrenia-
associated allele had overall higher levels 
of the short form transcript than those 
homozygous for the non-associated 
CAPON allele. They saw no differences in 
levels of the full-length transcript between 
the groups with different SNP genotypes. 
These are intriguing but preliminary 
results. Getting reliable results from 
studies on postmortem samples is 
extremely difﬁ  cult because of numerous 
confounding factors. Brzustowicz and 
colleagues tried to control for some 
of them (such as sex of the individual, 
substance abuse by the individual, 
and storage time of the sample), but 
others are impossible to determine or 
control for. Moreover, this particular 
collection of samples had only tissue 
from the dorsolateral prefrontal cortex 
available for study. Sample preparation 
was geared toward high-quality RNA for 
expression studies and not suitable for 
parallel protein analysis. Future studies, 
with at least some of them in animal 
models that allow controlled conditions 
and experimentation, will need to 
determine the functions of the long 
and short isoforms of CAPON and their 
interaction with other proteins involved 
in postsynaptic neurotransmission 
(some of which have also been linked to 
schizophrenia), and elucidate a possible 
role for CAPON in psychiatric disorders. 
Xu B, Wratten N, Charych EI, Buyske 
S, Firestein BL, et al. (2005) Increased 
expression in dorsolateral prefrontal 
cortex of CAPON in schizophrenia and 
bipolar disorder. DOI: 10.1371/journal.
pmed.0020263
The prevalence of asthma and allergy, 
deﬁ  ned as immunologically mediated 
hypersensitivity, is increasing. It is 
estimated that more than 20% of the 
world’s population has IgE-mediated 
allergic diseases. The scale of the clinical 
problem is immense. The World Health 
Organization estimates that asthma affects 
nearly 150 million people worldwide, and 
more than 180,000 deaths each year are 
due to asthma. Approximately US$20 
billion is spent globally each year on 
allergic rhinitis, including medications, 
time off work, and clinician consultations. 
The cost of allergy drugs alone is 
estimated to be US$8 billion per annum.
While allergy prevalence is increasing, 
the causal risk factors are still unknown. 
Matthias Wjst and colleagues 
investigated whether the spatial 
(latitude) and temporal (birth month) 
distribution of risk factors might offer 
insight into the mechanism of disease.
Previous studies have already 
shown that birth month is a risk factor 
associated with allergy; as the authors 
point out, birth month, used as a proxy 
for early allergen exposure, might be 
associated with upper respiratory 
infections during winter months. Studies 
have also associated geographical 
latitude with allergy. But some experts 
have noted that latitude, a proxy for 
ultraviolet solar exposure, might also 
reﬂ  ect climatic differences, genetic 
inﬂ  uences, or even cultural differences in 
the raising of children.
In this study, Wjst and colleagues 
tried to further understand the effects 
of latitude and birth date on the 
prevalence of allergy deﬁ  ned by markers 
such as allergic rhinitis, sensitization 
to grass or dust, and total IgE levels. 
They distributed a questionnaire to 
20– to 44–year-old individuals in 54 
centers across Europe, North Africa, 
India, North America, Australia, and New 
Zealand. Altogether, data from 200,682 
participants were analyzed.
The median prevalence of allergic 
rhinitis was 22%, but with a substantial 
variation across centers. They found 
allergic rhinitis decreased with 
geographical latitude, but there were 
many exceptions. There was no increase 
in prevalence during certain winters, and 
no altered risk by birth month, except 
borderline reduced risks in September 
or October. Altogether, the authors 
concluded that there was no major risk by 
being born in a particular month or during 
a particular season. There may be relevant 
birth month effects in single centers, but a 
global effect was questionable.
Previous research on the effect of birth 
month has also shown mixed results: 
differing studies have found associations 
that were positive, negative, or simply 
unclear.
But the authors noted that one 
difference of their study compared 
with others was the higher age of the 
subjects—interviewees were born 
between 1945 and 1973—and suggested 
that it might be possible that there are 
more marked symptoms in children that 
were being lost in adulthood.
Teasing Out the Effects of Latitude and Birth Date on Allergy
DOI: 10.1371/journal.pmed.0020375
DOI: 10.1371/journal.pmed.0020375.g001
World and European distribution of study centres
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Most previous studies have shown an 
association with allergic sensitization, 
indicating subclinical effects that 
gained importance only when occurring 
in combination with additional risk 
factors. One of the main advantages 
of this study—a standardized allergen 
test protocol—might, thus, be a 
disadvantage since the effects of local 
allergens might have been missed. 
Another methodological restriction 
might have been the use of self-
reported “hay fever.” This term may be 
used in a different way across Europe, 
said the authors.
Data on the geographical distribution 
of allergic diseases are rare, and, 
hence, this study is valuable. However, 
a previous meta-analysis has shown 
negative association of latitude and 
symptoms of allergic rhinitis, with a 
−0.05% decrease per degree. In this 
study, symptoms of allergic rhinitis 
decreased with geographical latitude 
on a worldwide scale, but not when 
the analysis was restricted to Europe 
alone. One intriguing possibility, which 
needs further work, is that a risk factor 
within language borders might be more 
relevant than geographical latitude alone 
in determining the distribution of allergic 
diseases.
Wjst M, Dharmage S, André E, Norback D, 
Raherison C, et al. (2005) Latitude, birth 
date, and allergy. DOI: 10.1371/journal.
pmed.0020294
Some people close their eyes when they listen to music; others 
wear earplugs when they read in noisy buses or airplanes. Both 
serve to block out inappropriate sensory stimulation when 
we try to focus, something that happens automatically when 
we concentrate. Neuroimaging studies have shown that this 
focusing process is regulated within our brains; when people 
undergo tasks that depend exclusively on visual clues, they not 
only activate the areas of the brain involved in visual processing 
but also deactivate those areas that have to do with auditory 
processing. The reverse activation/deactivation pattern is seen 
when the clues are exclusively auditory. This phenomenon, called 
“cross-modal auditory/visual deactivation,” is thought to help 
focus the information processing capacities of the brain on the 
relevant areas
Alexander Drzezga and colleagues are trying to understand 
the cognitive changes associated with Alzheimer disease (AD). 
AD has historically been categorized as a disease of memory loss, 
but more recent results suggest that the disease is associated 
with more fundamental deﬁ  cits in attention and perception. The 
researchers now report results from a study that examined the 
activation and deactivation patterns in the brains of patients with 
AD. The results suggest that patients with AD and patients with 
mild cognitive impairment (MCI) have problems focusing their 
brain activity: they show less activity than normal people in the 
“correct” brain areas but also more activity in the “wrong” areas.
To test whether cross-modal inhibition is affected in AD, the 
researchers recruited 32 participants, who fell into three age-
matched groups: 11 healthy individuals, 11 individuals with MCI, 
and ten individuals with moderate AD. All participants were trained 
to perform a navigation task, based exclusively on visual clues, in 
a virtual reality environment. All participants understood the task 
and the clues. They then each completed 12 separate positron 
emission tomography scans, eight during active navigation 
(ﬁ  nding their way from a starting point to a speciﬁ  c destination) 
and four under control conditions (traveling along a never-ending 
pathway). The tasks were performed in complete silence. 
The three groups differed in their performance—measured 
by the time needed to reach the destination—as would be 
expected. In addition, the researchers observed differences in their 
brain activation and deactivation patterns. Higher-order visual 
processing areas were activated to the greatest extent in healthy 
individuals, to a lesser extent in individuals with MCI, and not at all 
in individuals with AD. Similarly, cerebellar activation (suggesting 
movement automation) was absent in individuals with AD, present 
at low levels in individuals with MCI, and strongest in healthy 
individuals. Conversely, individuals with AD or MCI showed more 
activation in the (lower order) primary visual areas and in frontal 
cortical areas. This may indicate that sensory information gets 
“stuck” in lower levels of processing in AD. Regarding the inhibition 
of irrelevant input, strong bilateral deactivation in task-irrelevant 
auditory cortical regions was seen in healthy individuals. This was 
much less prominent in individuals with MCI, and individuals with 
AD showed no deactivation. 
The researchers conclude that “successful cognitive 
performance in healthy individuals is associated with 
deactivation of task-irrelevant cerebral regions, whereas the 
development of AD appears to be characterized by a progressive 
impairment of cross-modal cerebral deactivation functions.” 
They go on to propose that “orientation disability in the outside 
world seen in patients with AD may in fact be partially based on 
the inability to selectively orient spatial attention to task-relevant 
internal representations of perceptual stimuli.” The researchers 
are now in the middle of a follow-up study that concentrates on 
individuals with MCI—some of whom remain stable for years, 
whereas others progress to AD—to see whether the extent of 
cross-modal inhibition correlates with progression to disease. 
Drzezga A, Grimmer T, Peller M, Wermke M, Siebner H, et al. (2005) 
Impaired cross-modal inhibition in Alzheimer disease. DOI: 10.1371/
journal.pmed.0020288 
Alzheimer Disease: Failure to Tune Out Irrelevant Input?
DOI: 10.1371/journal.pmed.0020356
DOI: 10.1371/journal.pmed.0020356.g001
Cerebral activation and deactivation during spatial navigation
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One class of treatments commonly used for prevention 
and treatment of venous and arterial thrombosis is vitamin K 
antagonists (VKA), such as warfarin. The molecular target of 
these anticoagulants is the vitamin K epoxide reductase complex 
(VKORC) of which one component, VKORC1, was recently 
identiﬁ  ed. The gene for this component is mutated in individuals 
with combined deﬁ  ciency of vitamin K–dependent clotting 
factors type 2 or with warfarin resistance.
What makes VKA treatment so tedious for patients is that the 
dose of VKA required to achieve anticoagulation varies among 
patients and even changes over time in the same patient, so 
patients require regular monitoring to ensure that they are 
not over- or under-anticoagulated. The standard measure of 
anticoagulation is the international normalized ratio (INR). A 
recent study reported polymorphisms in the VKORC1 gene that 
explained up to 30% of the variation in the pharmacological 
response to VKAs, but few clinics take such inherited 
determinants of the pharmacological response into account.
In a paper published in PLoS Medicine, Dutch authors Pieter 
Reitsma and colleagues aimed to estimate the contribution of 
C1173T polymorphisms in the VKORC1 gene to dose requirement 
for the anticoagulants acenocoumarol and phenprocoumon and 
to bleeding risk. In this case-control study, the authors studied 
110 patients who bled during VKA therapy and 220 controls free 
of bleeding under the same therapy. Patients in the study were 
being treated with anticoagulants for venous thrombosis or were 
receiving anticoagulants to prevent arterial thromboembolism 
related to their atrial ﬁ  brillation or mechanical heart valves. 
What the authors found was that to achieve the same target 
INR, control patients with CT and TT genotypes required less 
phenprocoumon or acenocoumarol than control patients 
with the CC genotype. Also, compared with CC individuals, 
carriers of at least one T allele had increased bleeding risk in the 
phenprocoumon users but not in acenocoumarol users.
The results, although based on a small sample size of 
individuals, support the suggestion that bleeding risk 
for T carriers is higher in phenprocoumon users than in 
acenocoumarol users. If this suggestion is conﬁ  rmed in 
additional studies and extended to more frequently occurring 
and clinically relevant nonmajor bleeding, it may imply that 
CT and TT carriers should be preferentially treated with 
acenocoumarol, despite the fact that this anticoagulant gives 
poorer quality of control of treatment intensity.
At present, there is no clear explanation for risk differences 
between the two coumarin anticoagulants, the authors 
noted, although it is possible that the long half-life of 
phenprocoumon—a 140-hour half-life versus an 11-hour half-life 
of acenocoumarol—is a factor. 
Although this study needs to be repeated in other populations 
of patients, increased bleeding risk in some individuals supports 
the idea that genotyping for this polymorphism in the VKORC1
gene should be further explored. It may be that, in the future, 
genotyping will be a possibility for patients starting on 
acenocoumarol and phenprocoumon treatment in order to help 
identify those individuals who are at highest bleeding risk and 
who, thus, should be monitored more intensely.
Reitsma, PH, van der Heijden JF, Groot AP, Rosendaal FR, Büller 
HR (2005) A C1173T dimorphism in the VRKORC1 gene determines 
coumarin sensitivity and bleeding risk. DOI: 10.1371/journal.
pmed.0020312
Understanding Bleeding Risk after Anticoagulation
DOI: 10.1371/journal.pmed.0020352
Hookworms are intestinal parasites of 
mammals, including humans, dogs, and 
cats; in humans, these infections are a 
leading cause of intestinal blood loss and 
iron-deﬁ  ciency anemia. These infections 
occur mostly in tropical and subtropical 
climates, and are estimated to infect about 
1 billion people worldwide—about one-
ﬁ  fth of the world’s population. People who 
have direct contact with soil that contains 
human feces in areas where hookworm 
is common are at high risk of infection; 
because children play in dirt and often go 
barefoot, they are at highest risk.
However, since transmission of 
hookworm infection requires development 
of the larvae in soil, hookworm cannot be 
spread person to person. Anthelminthic 
chemotherapy with benzimidazole 
drugs is effective at eliminating existing 
adult parasites. But since reinfection 
occurs rapidly after treatment, making 
a vaccine against hookworm disease is 
a public health priority. Previous animal 
vaccine studies have had mixed results. 
Dogs have been successfully vaccinated 
against infection with the dog hookworm 
Ancylostoma caninum by immunization 
with attenuated third-stage infective 
larvae (L3). Varying levels of efﬁ  cacy have 
been reported for vaccination against the 
major antigens secreted by the same larval 
stage in hamsters and dogs. However, only 
partial reductions in parasite load have 
been reported. In addition, protective 
antigens from the larval stage are only 
expressed in larvae, not in adult worms; 
hence, antibodies against L3 secretions 
are useless against adult stage parasites in 
the gut.
In this month’s PLoS Medicine, Alex 
Loukas and colleagues suggest that 
the ideal hookworm vaccine would be 
a mixture of two recombinant proteins, 
targeting both the infective larva and the 
blood-feeding adult stage of the parasite. 
Such a vaccine would limit the amount of 
blood loss caused by feeding worms and 
maintain normal levels of hemoglobin, 
said the authors. This outcome is 
particularly important in young children 
and women of childbearing age, 
where menstrual and, particularly, fetal 
hemoglobin demands are high. 
Getting Closer to a Vaccine for Hookworm
DOI: 10.1371/journal.pmed.0020369
DOI: 10.1371/journal.pmed.0020369.g001
Hookworms secrete proteins that are being 
used as vaccines in animal models
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The endothelium plays a crucial role in the maintenance 
of vascular tone and structure. Endothelial dysfunction is 
associated with cardiovascular risk factors, metabolic diseases, 
and systemic or local inﬂ  ammation. One proposed mechanism 
for the development of endothelial dysfunction is the presence 
of elevated blood levels of asymmetric dimethylarginine 
(ADMA), an analogue of the amino acid L-arginine. The 
concentration of ADMA in the plasma of healthy adults varies 
between 0.4 µM and 1 µM, but it may increase to the range 
1.45–4.0 µM in certain diseases. 
Elevated ADMA is now widely recognized as a risk marker 
for vascular disease. Circulating concentrations of ADMA 
are increased in patients with renal failure, pulmonary 
hypertension, heart failure, hypercholesterolemia, and a range 
of other conditions associated with cardiovascular disease. In 
patients with end-stage renal failure, plasma levels of ADMA 
have been shown to predict mortality and cardiovascular 
outcome, and in a cohort of otherwise healthy men, those with 
the highest levels of ADMA had increased risk of acute coronary 
events. Increased circulating ADMA in pregnant women 
predicts increased risk of pre-eclampsia and intrauterine 
growth retardation.
But is ADMA just a risk marker, or does it have a causal role 
in the pathophysiology of cardiovascular disease? ADMA 
inhibits the formation of nitric oxide, a major endothelium-
derived vasoactive mediator, and the most potent endogenous 
vasodilator known. An elevated level of ADMA could, thus, 
impair vascular function. However, some have argued that 
the concentration of ADMA found in plasma, even in disease 
states, is too low to be an effective inhibitor of nitric oxide 
synthase, and that the usual concentrations of arginine in cells 
should overcome any inhibitory effects of ADMA on nitric oxide 
synthase. In order to determine how ADMA might exert effects 
on endothelial cells and produce pathology, Caroline Smith and 
colleagues assessed the effects of ADMA on gene expression. 
The researchers treated human coronary artery endothelial 
cells with ADMA, and used microarrays to measure the effects 
on gene expression. They detected substantial changes in 
gene expression in these cells after 24 hours of exposure 
DOI: 10.1371/journal.pmed.0020331.g001
ADMA’s effects on endothelial gene expression
ADMA in Vascular Disease: More than a Marker?
DOI: 10.1371/journal.pmed.0020331
Of the different proteins expressed 
by blood-feeding parasitic helminths, 
proteolytic enzymes have shown 
promise as intervention targets for 
vaccine development. A previous study 
in which dogs were vaccinated with a 
catalytically active recombinant cysteine 
hemoglobinase, Ac-CP-2, induced 
antibodies that neutralized proteolytic 
activity, and provided partial protection 
to vaccinated dogs by reducing egg 
output and worm size, but there were 
not signiﬁ  cant reductions of adult worm 
burdens or blood loss.
In the present study, the researchers 
found that vaccination of dogs with 
recombinant Ac-APR-1, an aspartic 
hemoglobinase that initiates the 
hemoglobin digestion cascade in 
hookworms, induced antibody and 
cellular responses, and resulted in 
signiﬁ  cantly reduced hookworm burdens 
and fecal egg counts in vaccinated dogs 
compared to control dogs after challenge 
with infective larvae of A. caninum. Most 
importantly, vaccinated dogs were 
protected against blood loss and most did 
not develop anemia, the major pathologic 
sequelae of hookworm disease.
The authors went on to show that 
IgG from vaccinated animals decreased 
the catalytic activity of the recombinant 
enzyme in vitro, and the antibody 
bound in situ to the intestines of worms 
recovered from vaccinated dogs, 
implying that the vaccine interfered with 
the parasite’s ability to digest blood.
This result of vaccination against APR-
1 shows the best efﬁ  cacy so far reported 
for a recombinant vaccine aimed 
at reducing hookworm egg counts, 
intestinal worm burdens, and hookworm-
induced blood loss, say the authors. They 
suggest that vaccination with APR-1 
damaged the parasite’s intestine and 
resulted in decreased blood intake by 
feeding worms, and, hence, reduced 
blood loss from the dogs. 
The authors go on to suggest 
that the optimal hookworm vaccine 
would combine two elements: one to 
prevent L3 from developing into adult 
blood-feeding hookworms, and one to 
block the establishment, survival, and 
fecundity of the adult parasites in the 
intestine. Achieving both goals would 
require a vaccine comprised of an L3 
antigen, such as ASP-2, which is now 
under clinical development, and an adult 
gut protease, such as APR-1.
These results have implications 
for human hookworm vaccine 
development; the authors finish by 
saying that there is now enough 
evidence to conclude that the 
counterpart vaccine for the major 
human hookworm Necator americanus
(Na-APR-1) should be developed and 
entered into human clinical trials.
Loukas A, Bethony JM, Mendez S, Fujiwara 
RT, Goud GN, et al. (2005) Vaccination 
with recombinant aspartic hemoglobinase 
reduces parasite load and blood loss after 
hookworm infection in dogs. DOI: 10.1371/
journal.pmed.0020295
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to concentrations of ADMA similar to those reported in 
pathophysiological states. Changes in several genes were 
conﬁ  rmed by Northern blotting, quantitative PCR, and in 
some instances, at the protein level, by Western blotting. 
To determine whether such changes also occur in vivo, the 
team examined tissues from mice with elevated ADMA levels. 
Some of the genes exhibiting consistent changes pointed to 
pathways known to be associated with cardiovascular risk and 
pulmonary hypertension. 
Smith and colleagues concluded that the concentrations 
of ADMA found in disease states affect the transcriptional 
proﬁ  le of endothelial cells. Moreover, their results suggest novel 
mechanisms by which ADMA might contribute to or cause 
disease. Changes in bone morphogenetic protein signaling, and 
in enzymes involved in arginine methylation, may be particularly 
relevant to understanding the pathophysiological signiﬁ  cance of 
raised ADMA levels. The effects on bone morphogenetic protein 
signaling may be important in renal disease and in the link 
between raised ADMA and pulmonary hypertension. The hope is 
that in the long-term understanding the mechanisms by which 
increased ADMA contributes to cardiovascular diseases might 
suggest new therapeutic strategies. 
Smith CL, Anthony S, Hubank M, Leiper JM, Vallance P (2005) 
Effects of ADMA upon gene expression: An insight into the 
pathophysiological signiﬁ  cance of raised plasma ADMA. DOI: 
10.1371/journal.pmed.0020264
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